Ticker Details
Prelude Therapeutics Inc.
IPO Date:	September 25, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$174.77M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.54 | 4.56%
Avg Daily Range (30 D):	$0.12 | 5.72%
Avg Daily Range (90 D):	$0.14 | 7.74%

Institutional Daily Volume
Avg Daily Volume:	.24M
Avg Daily Volume (30 D):	.41M
Avg Daily Volume (90 D):	1.09M

Trade Size
Avg Trade Size (Sh.):	128
Avg Trade Size (Sh.) (30 D):	157
Avg Trade Size (Sh.) (90 D):	192

Institutional Trades
Total Institutional Trades:	335
Avg Institutional Trade:	$1.97M
Avg Institutional Trade (30 D):	$1.11M
Avg Institutional Trade (90 D):	$.83M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.35M
Avg Closing Trade (30 D):	$.55M
Avg Closing Trade (90 D):	$.55M
Avg Closing Volume:	88.73K

News

Dec 6, 2025 @ 4:00 PM Prelude Therapeutics Presents Data at the 2025 ASH... Source: Prelude Therapeutics

Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai

Sep 13, 2024 @ 2:00 PM Prelude Therapeutics’ SMARCA2 Degrader PRT3... Source: Prelude Therapeutics Incorporated

Jun 3, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Upcoming He... Source: Prelude Therapeutics, Inc.

May 9, 2024 @ 11:01 AM Prelude Therapeutics to Participate in Citizens JM... Source: Prelude Therapeutics, Inc.

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-1.47	$-.26	$-.41
Diluted EPS	$-1.47	$-.26	$-.41
Revenue	$10.5M	$6.5M	$M
Gross Profit
Net Income / Loss	$-111.77M	$-19.73M	$-31.23M
Operating Income / Loss	$-121.05M	$-20.42M	$-32.19M
Cost of Revenue
Net Cash Flow	$35.59M	$20.97M	$-14.52M
PE Ratio